Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
GC022F
BIOLOGICAL
2 trials
Sponsors
Hebei Yanda Ludaopei Hospital
Conditions
B-cell Acute Lymphoblastic Leukemia
B-cell Non Hodgkin Lymphoma
Early Phase 1
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
NCT04129099
Hebei Yanda Ludaopei Hospital
B-cell Acute Lymphoblastic Leukemia
Start: 2019-10-22
End: 2022-06-30
Target: 18
Updated: 2020-05-28
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL
NCT04412174
Hebei Yanda Ludaopei Hospital
B-cell Non Hodgkin Lymphoma
Start: 2020-06-30
End: 2022-12-31
Target: 18
Updated: 2020-06-02
Related Papers
Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Blood
2020-11-04
16 citations